Aims: The cytosolic 5'-nucleotidase-III (NT5C3) is involved in the metabolism of the nucleoside analog, cytosine arabinose (AraC), and the expression level of NT5C3 is correlated with sensitivity to AraC in acute myeloid leukemia (AML) patients. The current study examined whether the NT5C3 polymorphisms could affect chemotherapy outcomes in 103 Korean AML patients.
Methods: Forty-seven single nucleotide polymorphisms in NT5C3 were genotyped using the Illumina GoldenGate genotyping assay. The genetic effects of the polymorphisms on the outcome of chemotherapy were analyzed using χ and logistic regression models.
Results: Although none of the NT5C3 polymorphisms was associated with a complete remission rate, a common single nucleotide polymorphism, rs3750117, showed a significant association with induction rate after the first course of chemotherapy (Pcorr=0.004 and odds ratio=11.28) in AML patients. In addition, NT5C3 expression levels were significantly increased in patients with risk allele homozygote.
Conclusions: The data suggest that genotyping the NT5C3 polymorphism may have the potential to identify patients more likely to respond to AraC-based chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/FPC.0000000000000072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pyrimidine-5'-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5'-nucleotidase type I deficiency and influence of Gilbert's Syndrome on clinical expression.
Blood Cells Mol Dis
December 2014
Hemocentro e Instituto Nacional de Ciência e Tecnologia do Sangue, Universidade de Campinas, São Paulo, Brazil. Electronic address:
Pyrimidine-5'-nucleotidase type I (P5'NI) deficiency is an autosomal recessive condition that causes nonspherocytic hemolytic anemia, characterized by marked basophilic stippling and pyrimidine nucleotide accumulation in erythrocytes. We herein present two African descendant patients, father and daughter, with P5'N deficiency, both born from first cousins. Investigation of the promoter polymorphism of the uridine diphospho glucuronosyl transferase 1A (UGT1A) gene revealed that the father was homozygous for the allele (TA7) and the daughter heterozygous (TA6/TA7).
View Article and Find Full Text PDFNT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.
Pharmacogenet Genomics
September 2014
aCancer Research Institute bDepartment of Internal Medicine, Seoul National University College of Medicine cClinical Research Institute, Seoul National University Hospital dDepartment of Genetic Epidemiology, SNP Genetics Inc. eFunctional Genome Institute, PDXen Biosystem Inc. fDepartment of Life Science, Sogang University, Seoul, Korea.
Aims: The cytosolic 5'-nucleotidase-III (NT5C3) is involved in the metabolism of the nucleoside analog, cytosine arabinose (AraC), and the expression level of NT5C3 is correlated with sensitivity to AraC in acute myeloid leukemia (AML) patients. The current study examined whether the NT5C3 polymorphisms could affect chemotherapy outcomes in 103 Korean AML patients.
Methods: Forty-seven single nucleotide polymorphisms in NT5C3 were genotyped using the Illumina GoldenGate genotyping assay.
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Pharmacogenomics
July 2012
Department of Experimental & Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Article Synopsis
- The study explores the link between genetic variations (SNPs) in specific genes related to the gemcitabine pathway and the drug's pharmacokinetics in solid tumor patients.
- Significant associations were found between gemcitabine clearance and SNPs in the NT5C2 gene, as well as impacts of other gene SNPs (CDA, SLC29A1) on the clearance of gemcitabine metabolites.
- Findings suggest that understanding these genetic variations could help tailor gemcitabine treatment for individual patients, potentially improving therapy outcomes in solid tumor cases.
Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.
Pharmacogenet Genomics
August 2009
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.
Background: 5'-Nucleotidases play a critical role in nucleotide pool balance and in the metabolism of nucleoside analogs such as gemcitabine and cytosine arabinoside (AraC). We previously performed an expression array association study with gemcitabine and AraC cytotoxicity using 197 human lymphoblastoid cell lines. One gene that was significantly associated with gemcitabine cytotoxicity was a nucleotidase family member, NT5C3.
View Article and Find Full Text PDFDifferential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.
Drug Metab Dispos
December 2008
Laboratoire de Cytologie Analytique, INSERM U590, Faculté de Médecine Rockefeller, 8, Avenue Rockefeller, 69008 Lyon, France.
mRNA expression levels of certain genes have shown predictive value for the outcome of cytarabine-treated AML-patients. We hypothesized that genetic variants play a role in the regulation of the transcription of these genes. We studied leukoblasts from 82 patients with acute myeloid leukemia and observed various extent and frequency of differential allelic expression in the CDA, DCK, NT5C2, NT5C3, and TP53 genes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!